PHR vs. MPLN, AHCO, OMCL, SLNO, IRWD, BKD, NVCR, WRBY, FDMT, and VRNA
Should you be buying Phreesia stock or one of its competitors? The main competitors of Phreesia include MultiPlan (MPLN), AdaptHealth (AHCO), Omnicell (OMCL), Soleno Therapeutics (SLNO), Ironwood Pharmaceuticals (IRWD), Brookdale Senior Living (BKD), NovoCure (NVCR), Warby Parker (WRBY), 4D Molecular Therapeutics (FDMT), and Verona Pharma (VRNA). These companies are all part of the "medical" sector.
Phreesia (NYSE:PHR) and MultiPlan (NYSE:MPLN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, community ranking, risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation.
Phreesia has a beta of 0.92, suggesting that its share price is 8% less volatile than the S&P 500. Comparatively, MultiPlan has a beta of 0.6, suggesting that its share price is 40% less volatile than the S&P 500.
MultiPlan has a net margin of -9.54% compared to Phreesia's net margin of -38.42%. MultiPlan's return on equity of -8.31% beat Phreesia's return on equity.
In the previous week, Phreesia had 3 more articles in the media than MultiPlan. MarketBeat recorded 4 mentions for Phreesia and 1 mentions for MultiPlan. MultiPlan's average media sentiment score of 1.00 beat Phreesia's score of 0.47 indicating that MultiPlan is being referred to more favorably in the news media.
Phreesia received 113 more outperform votes than MultiPlan when rated by MarketBeat users. Likewise, 64.74% of users gave Phreesia an outperform vote while only 41.67% of users gave MultiPlan an outperform vote.
MultiPlan has higher revenue and earnings than Phreesia. Phreesia is trading at a lower price-to-earnings ratio than MultiPlan, indicating that it is currently the more affordable of the two stocks.
Phreesia currently has a consensus target price of $31.62, suggesting a potential upside of 53.55%. MultiPlan has a consensus target price of $2.00, suggesting a potential upside of 247.04%. Given MultiPlan's higher probable upside, analysts clearly believe MultiPlan is more favorable than Phreesia.
92.1% of Phreesia shares are held by institutional investors. Comparatively, 87.2% of MultiPlan shares are held by institutional investors. 5.8% of Phreesia shares are held by company insiders. Comparatively, 8.2% of MultiPlan shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
MultiPlan beats Phreesia on 10 of the 17 factors compared between the two stocks.
Get Phreesia News Delivered to You Automatically
Sign up to receive the latest news and ratings for PHR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PHR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Phreesia Competitors List
Related Companies and Tools
